Introduction 17
Classical therapeutic antibodies commonly target cell surface or secreted antigens 18 but are unable to access intracellular proteins. However, intracellular proteins are 19 degraded by proteasome-dependent and independent mechanisms, resulting in the 20 generation of peptides for surface presentation by major histocompatibility complex 21 1 Generation of HLA-A2 tetramers 2 A bacterial expression construct encoding the human HLA-A*0201 extracellular 3 domain (amino acids 24-293) fused with a C-terminal BirA biotinylation sequence 4 (LNDIFEAQKIEWH), and separate construct expressing mature human β2 5 microglobulin (β2m, amino acids 21-119), were each generated and transformed into 6 competent Escherichia coli strain BL21(DE3). Protein expression was induced by 7 addition of 0.5mM IPTG in low-salt LB medium (1% Tryptone, 0.5% Yeast extract 8 and 0.5% NaCl w/v), and insoluble inclusion bodies containing the recombinant 9 proteins were purified using BugBuster (Merck, #70750-3), according to the 10 manufacturer's instructions. Peptides were synthesized by the peptide synthesis 11 facility in the Weatherall Institute of Molecular Medicine (University of Oxford). 12
HLA-A2 tetramers were generated as previously described (16, 17) . Briefly, HLA-13 A*0201 (15mg), β2m (12.5mg) and peptide (5mg) were added into 500ml of refolding 14 buffer (100mM Tris.Cl pH8.0, 400mM L-Arginine, 2mM EDTA, 5mM reduced-15 glutathione, 0.5mM oxidized-glutathione, and 0.1mM PMSF) and refolded for 48h. 16
The refolding complex was concentrated and buffer exchanged to 10mM Tris-HCl 17 pH8.0, then biotinylated with BirA protein biotin ligase (Avidity LLC, #BirA500). 18
Biotinylated protein was then separated using an Akta Purifier FPLC with a 19
Sephadex 75 column and HLA-A2/β2m/peptide monomers were isolated and 20 subsequently stored at -80°C. Aliquots were thawed and tetramerized with Extravidin 21 (Sigma-Aldrich, #E2511) on use. 22 23
Generation of anti-p53 TCRm monoclonal antibodies 24
All in vivo work was approved by local ethics review committee and governed by 25 appropriate Home Office establishment, project and personal licenses. MF1 mice (6-26 8 week old females) were immunized with the HLA-A*0201/p53 tetramers 4 times 27 with 100 μg tetramer at 10 day intervals and fusions were performed two days after 28
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Author Manuscript Published OnlineFirst on March 31, 2017; DOI: 10.1158/0008-5472. the final immunization. A standard fusion protocol was followed(18) with NS0 murine 1 myeloma cells as the fusion partner, and hybridomas were grown out under 2 hypoxanthine, aminopterin and thymidine (HAT) selection. Hybridoma supernatants 3 were screened for the presence of secreted antibodies specifically, or preferentially, 4 recognizing the immunizing tetramer rather than a control tetramer by ELISA. 5
Positive hybridoma colonies were expanded and cloned by limiting dilution for further 6 validation. 7 8
Production of purified antibodies 9
Production of purified TCRm antibodies from hybridoma supernatant was achieved 10 by culturing hybridoma cells in serum-free medium to extinction, or in CL350 11 bioreactors (Sigma-Aldrich, #Z688037), followed by protein A or protein G purification 12 of immunoglobulin. 13
Endotoxin-free recombinant T1-116C antibody (mIgG1) production, and its isotype 14 switching (mIgG2a or hIgG1), were outsourced to Absolute Antibody Ltd after the 15 antibody variable region cDNAs were cloned based on a published method (19) . 16
Briefly, T1-116C heavy and light chains were cloned into pUV vectors, then 17 transiently transfected into ABS293 cells. Culture supernatants were harvested and 18 antibody purified through Protein A affinity chromatography. Purified antibody was 19 analyzed by SDS-PAGE and endotoxin level was determined by LAL chromogenic 20 endotoxin assay (Thermo Scientific, #88282). 21
T2 cell binding assay 23
TAP-deficient T2 cells cultured at logarithmic phase were pulsed with peptides at 24 100mM (or a range of lower concentrations for peptide titration experiments) for 12-25 16h in a flat bottom 96-well tissue culture plate under standard cell culture conditions. 26
Cells were then harvested and stained with TCRm antibodies and/or HLA-A2-specific 27 mAb BB7.2 (Abcam, #ab74674), followed by APC conjugated goat anti-mouse 28
Author Manuscript Published OnlineFirst on March 31, 2017; DOI: 10.1158/0008-5472. secondary antibody (eBioscience, #17-4010-82). Samples were washed with FACS 1 wash buffer (2% FBS in PBS + 0.1% sodium azide) then fixed with 1% 2 paraformaldehyde (in PBS) and acquired with a FACSCalibur (BD Biosciences). 3 4
Western blotting 5
Whole cell lysates were prepared using Mammalian Protein Extraction Reagent 6 (Thermo Scientific, 78503) containing a nuclease to degrade any nucleic acids and 7 additional protease and phosphatase inhibitors. Protein concentrations were 8 quantified using BCA assay (Thermo Scientific, 23227). 30μg whole cell lysates were 9 resolved on 10% polyacrylamide gels and transferred to Protran™ nitrocellulose 10 membranes (GE Healthcare, 15269794). Membranes were blocked in 5% (w/v) low 11 fat milk in PBS for 1 hour at RT, and were then incubated with primary antibodies 12 overnight at 4°C diluted in 5% (w/v) low fat milk in PBS (mouse anti-p53 (DO-1, 13
Santa Cruz Biotechnology, sc-126, 1ug/ml); mouse anti-p53 (DO-7, Santa Cruz 14
Biotechnology, sc-47698, 1ug/ml); mouse anti-p53 (Pab1801, Santa Cruz 15
Biotechnology, sc-98, 1ug/ml); mouse anti-β-Actin (Sigma, clone AC-15) 1:20,000). 16
This was followed by washing of the membranes in PBS (three washes) and PBS-17
Tween (0.1% v/v, one wash) at RT (5 minutes each wash) then incubation in 18 secondary antibody solution (goat anti-mouse IgG-HRP (Dako, P0447) diluted1/5000 19 in 5% (w/v) low fat milk in PBS) for 1 hour at RT. After washing as above, antibody 20 binding was detected using ECL reagent (GE Healthcare, RPN2106) and visualized 21 with a G:BOX ChemiXRQ imaging system (Syngene). 22
23

Mass spectrometry identifying HLA-I associated peptides 24
Sample processing and data analysis were carried out as previously described (20) . 25 Briefly, 10 9 MDA-MB-231 and MCF-7 cells were lysed and cleared by centrifuging at 26 300g for 10min at 4°C to remove nuclei, followed by 15000g for 45min at 4°C to 27 pellet other insoluble material. HLA complexes were captured by rotating 1ml W6/32 28 Beads were re-packed in the column and washed by using subsequent runs of ice-2 cold 50mM Tris buffer (pH 8.0) containing first 150mM NaCl and 0.005% NP40, then 3 150mM NaCl, followed by 400mM NaCl and lastly just 50mM Tris buffer. HLA-4 peptide complexes were eluted by using 5ml ice-cold 10% acetic acid and dried. 5
Samples were analyzed on an Ultimate 3000 HPLC system (Thermo Scientific) 6 online coupled to a Q-Exactive Hybrid Quadrupole-Orbitra Mass Spectrometer 7 (Thermo Scientific). Raw data were analyzed using Peaks 7.5 (Bioinformatics 8 solutions) with a database containing all annotated human SwissProt entries. 9
Quantitation of antibody molecules bound per target cell 11
Cell lines or T2 cells pulsed with the RMPEAAPPV peptide at 0.5-100µM 12 concentrations or the Flu peptide at 100µM were stained with PE-conjugated T1-13 116C mAb (mAb:PE = 1:1) or an isotype matched control antibody at 10μg/ml for 14 30min on ice. Cells were washed with FACS Wash buffer then fixed with 1% 15 paraformaldehyde before being analyzed with a FACSCalibur (BD Biosciences). plated in a flat-bottom 96-well plate the day before the assay was performed as 8 previously described(21). In brief, target cells were labeled with Carboxyfluorescein 9 succinimidyl ester (CFSE) at RT before being washed once in RPMI media. The 10 CFSE labeled cells were opsonised with antibody for 30min at 4°C, washed once and 11 then 2.5x10 5 opsonized target cells added to the BMDM and left to co-culture at 37°C 12 for 1h. The BMDM were labeled with anti-F4/80-APC (AbD Serotec, #MCA497APC) 13 and the wells washed with PBS, before removal and analysis of the cells on 14 and suspended in RPMI. The labeled cells were opsonized with antibody for 30min 24 at 4°C before washing once in RPMI media. The target cells and PBMC effector 25 cells were co-cultured at a 50:1 (Effector:Target) ratio for 4h at 37°C. The cells were 26 pelleted by centrifugation (1500rpm for 5min), the supernatant transferred to a white 27 96-well plate, and read using a Varioskan Flash (Thermo Scientific) to record calcein 28 release (excitation wavelength 485nm; emission wavelength 530nm). Per cent of 1 maximum lysis was defined as the calcein release compared to the response 2 recorded when cells were treated with 4% TritonX-100 solution. Means from 3 triplicate wells from each condition were calculated. 4 5 Antibody radiolabeling 6 T1-116C-mIgG2a and an isotype control antibody (Absolute Antibody Ltd) were 7 radiolabeled with 111 In as previously described(22). Briefly, 500μg of T1-116C or 8 isotype control antibody was dissolved in 0.1M sodium bicarbonate aqueous buffer 9 (pH 8.2) before adding a 20-fold molar excess of 2-(4-isothiocyanatobenzyl)-10 diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA; Macrocyclics) and incubating 11 for 1h at 37°C. The DTPA-conjugated antibody was subsequently purified using a 12
Sephadex G50 gel filtration column and radiolabeled using 111 In-chloride (1MBq per 13 1µg of IgG). The protein was further purified by Sephadex G50 size exclusion 14 chromatography. Radiochemical purity was determined by instant thin layer 15 chromatography (iTLC) as >95%. 16
In vivo imaging and biodistribution 18
Female BALB/c nu/nu mice (Charles Rivers Laboratories) were injected 19 subcutaneously on their flanks with 1x10 6 MDA-MB-231 or MDA-MB-468 breast 20 cancer cells. 111 In-labeled T1-116C or mIgG2a isotype control antibody (5MBq, 5μg) 21 was administered intravenously when tumor sizes reached 120mm 3 at day 20, and 22 SPECT/CT imaging was performed at 24, 48, 72h after injection, using a Bioscan 23 NanoSPECT/CT. Volume-of-interest analysis was performed on SPECT images 24 using the Inveon Research Workplace software package (Siemens). After imaging at 25 72h post injection, animals were sacrificed and selected organs were removed, Charles River Laboratories). Animals were randomly grouped and antibodies or PBS 7 was administered twice a week (10mg/kg for Ab and 200μl for PBS) by 8 intraperitoneal injection. Tumor sizes were calculated as length x width x height x π / 9 6. Geometric Mean Diameter (GMD) was calculated as (L x W x H) 1/3 . Student t test 10 was used to evaluate the growth curves. 11 12
Results
13
Generation of p53/HLA-A2 murine monoclonal antibodies 14
A peptide derived from an N-terminal region of wild-type p53 that is rarely mutated 15 was selected to enable targeting of the maximal number of potential patients, 16
including those carrying the most common mutations leading to premature 17 termination of p53 translation (R196X and R213X). This p53 65-73 peptide 18 RMPEAAPPV (p53RMP) has also been proven to have endogenous 19 presentation(23,24) and has been tested in clinical trials of p53 vaccines without 20 patients experiencing any adverse side effects (7) . HLA-A2/p53RMP tetramers were 21 produced and shown to be able to display the p53RMP peptide to T cells 22 ( Supplementary Fig.1) . These tetramers were used as the immunogen to generate 23
TCRm mAbs recognizing p53RMP presented by HLA-A2 using classical hybridoma 24 technology. Hybridoma supernatants were screened for reactivity against the 25 immunizing p53RMP tetramer, and for specificity by their lack of binding to a tetramer 26 comprising HLA-A2 with a non-related peptide derived from influenza A virus M1 27
Author Manuscript Published OnlineFirst on March 31, 2017; DOI: 10.1158/0008-5472.CAN-16-3247 protein (Flu), by ELISA. Unsurprisingly the majority of the antibodies failed to 1 demonstrate specificity for the p53RMP containing tetramer and thus recognized the 2 MHC portion of the complex (a representative example is illustrated in 3 Supplementary Fig.2) . 4
The T1-116C hybridoma stably secreted antibodies recognizing the immunizing p53 5 tetramer but not the control tetramer by ELISA ( Supplementary Fig.2) . Antibody 6 binding specificity towards the p53RMP peptide was further validated on the surface 7 of human T2 lymphoblast cells. T2 cells are deficient in the transporter associated 8 with antigen processing (TAP) and pulsing them with an HLA-A2-binding peptide 9 stabilizes the HLA-A2/peptide complex on the cell surface. T1-116C antibodies 10 stained the cell surface of T2 cells pulsed with the target p53RMP peptide but not T2 11 cells pulsed with the Flu peptide, survivin and HCMV peptides or non-target peptides 12 derived from p53 ( Fig.1a ). 13
The T1-116C antibody was protein A purified from the hybridoma supernatants and 14 was further tested for a dose response in its binding to the p53RMP/HLA-A2 complex 15 on the cell surface. T2 cells pulsed with the p53RMP peptide showed increased T1-16 116C binding when the antibody concentration increased; this was saturated at 5 17 μg/ml ( Fig.1b ). Likewise, increasing peptide concentrations in the T2 cell assay also 18 enabled increased T1-116C binding ( Fig.1c ). On both occasions, T1-116C binding 19 was proportionally lower than that of the BB7.2 antibody, which detects HLA-A2 20 expression on the cell surface independently of the peptide being presented. 21
22
T1-116C binding is predominantly restricted to cancer cell lines with HLA-A2 23 and p53 expression 24
Having validated the specificity of T1-116C binding, we investigated whether the mAb tested for T1-116C mAb binding, and representative staining is shown in Fig.2a . As 1 summarized in Table 1, the T1-116C antibody was able to label cell lines expressed detectable p53 protein) ( Fig.2b and Supplementary Fig.3 ). There was 10 no T1-116C labeling of the HLA-A2 + Thiel cell line in which p53 protein expression 11 was undetectable by either Western blotting ( Fig.2b ) or immunocytochemistry (data 12 not shown). However, HL-60 cells lacked both HLA-A2 and p53 protein expression 13 and were bound by the T1-116C antibody (Supplementary Fig.3) . The epitope 14 bound by T1-116C on HL-60 cells is as yet unknown, but the binding does not seem 15
to represent epitope independent binding by the Fc receptors expressed on HL-60 16 cells, as control antibodies with the same isotype did not bind. 17
Neither the level of p53 protein nor transcript expression was an accurate indicator of 18 the intensity of T1-116C staining ( Fig.2b, Table 1, Supplementary Fig.4 ). This is 19 consistent with reports of p53 turnover, rather than steady-state levels, determining 20 the presentation of epitopes by MHC class I to CTLs(25). Proteasome inhibition using 21 the inhibitor bortezomib significantly increased the levels of detectable p53 protein 22 after 24 hours in NCI-H1395 cells (Supplementary Fig.5 ). This demonstrates that 23 p53 is normally actively being turned over in these cells and is consistent with this 24 leading to p53 peptide presentation and strong T1-116C staining despite low levels of demonstrated by flow cytometry of a T2 stabilization assay ( Fig.3c ). 20
The expression of p53 in normal tissues has been linked to radiation-sensitivity, with 21 hematopoietic tissues being among the normal adult tissues exhibiting the highest 22 levels of p53 protein (28, 29 Fig.6a ). The single positive donor (Buf21), who 1 only exhibited weak staining, had an abnormally high expansion of granulocytes 2 ( Supplementary Fig.6b ), which may be indicative of some potential abnormality. A 3 non-exhaustive list of potential health problems associated with such granulocytosis 4 includes leukemia, bacterial infection and autoimmune disorders. These data indicate 5 that the T1-116C antibody discriminates between p53 + /HLA-A2 + normal and tumor 6 cells. This is consistent with reports from studies using T cells which indicated that 7 malignant cells have increased p53 epitope presentation(25,31,32). The original T1-116C mAb was a murine IgG1/κ isotype. For further functional 22 studies, a human IgG1 chimeric antibody (hIgG1) and a mouse IgG2a (mIgG2a) 23 antibody were generated by transferring the heavy and light chain variable regions of 24 T1-116C into hIgG1 and mIgG2a backbones, respectively. The recombinantly 25 produced antibodies retained the binding specificity of the original antibody purified 26 from hybridoma supernatant (Fig.4a) . Several TCRm antibodies against cancer targets have been shown to have in vivo 1 activity against tumors by mediating immune effector mechanisms such as 2 complement-dependent cytotoxicity (CDC), antibody dependent phagocytosis 3 (ADCP) and/or antibody-dependent cellular cytotoxicity (ADCC) (4, 35, 36) . The ability 4 of a chimeric T1-116C antibody with a human IgG1 Fc domain to engage human 5 immune effector cells was tested against B-cell lymphoma cell lines displaying high 6 T1-116C binding, with rituximab (anti-CD20) used as a positive control (Fig.4b ). The 7 T1-116C antibody was able to engage immune effector cells to kill both OCI-Ly1 and 8
OCI-Ly8 B-cell lymphoma cell lines by ADCP, albeit less effectively than rituximab, 9
with the highest dose (10µg/ml) exhibiting the greatest effect. The T1-116C antibody 10 did not convincingly demonstrate significant killing by ADCC. Intriguingly, the CDC 11 killing mediated by T1-116C against OCI-Ly8 cells was higher than that achieved 12 with rituximab at the two higher antibody concentrations. 13
14
T1-116C binds to and inhibits the growth of breast cancer xenografts in vivo 15
Antibody biodistribution in vivo gives a good indication of antibody uptake and 16 clearance, including specific targeting to the tumor. For this purpose, T1-116C 17 (mIgG2a) was conjugated to the metal ion chelator pSCN-BnDTPA, which allowed 18 radiolabeling with 111 In chloride. The biodistribution of the radiolabeled antibody 19 following intravenous administration(37) was compared to that of a non-targeting 20 isotype control antibody in athymic mice bearing breast cancer xenografts that bind 21 T1-116C in vitro, (MDA-MB-231) or those that lack in vitro T1-116C binding (MDA-22 MB-468) using Single Photon Emission Computed Tomography (SPECT) (Fig.5a) . 23
Radiolabeled T1-116C and the isotype control followed a pattern of blood clearance, 24 and tumor and tissue uptake that is consistent with other radiolabeled whole 25 antibodies(37). Initially, the radiolabeled antibodies were observed in the blood, as liver. The amount of radiolabeled antibody in the blood then gradually decreased 1 over time, while uptake in the MDA-MB-231 tumor increased to over 25 per cent of 2 the injected dose per gram (%ID/g) at 72 h post injection (Fig. 5b) , thus increasing 3 tumor-to-blood ratio, as indicated by tumor-to-heart uptake levels (Fig. 5c) . MDA-MB-4 231 tumors, but not the MDA-MB-468 tumors showed higher uptake of T1-116C 5 (p<0.001 at 48 h post injection) compared to the isotype control antibody. 6
Biodistribution after dissection (Fig. 5d) confirmed a significantly higher uptake of 7 radiolabeled T1-116C in MDA-MB-231 tumor tissues compared to normal tissues 8 (p<0.0001), compared to MDA-MB-468 (p<0.0001) and compared to the control 9 antibody (p<0.0001). 10
To investigate whether T1-116C antibody has any effect on in vivo tumor growth, 11 recombinant T1-116C in either hIgG1 or mIgG2a formats were tested for their ability 12
to prevent the engraftment of MDA-MB-231 tumors in BALB/c nu/nu mice (10mg/kg, 13 twice weekly). The T1-116C mIgG2a format antibody significantly inhibited tumor 14 growth in vivo (P<0.0001) (Fig.6a ). The hIgG1 format T1-116C antibody did not 15 significantly affect tumor growth. Although hIgG1 can bind all activating murine 16
FcγRs, it has been reported to be less potent than mIgG2a antibodies in mouse 17 models(38), which likely contributes to the differences observed. 18
The T1-116C mIgG2a antibody was further tested for its ability to prevent the growth 19 of established MDA-MB-231 tumors in BALB/c nu/nu mice (Fig.6b ). Compared to an 20 isotype matched control antibody (anti-fluorescein) or PBS carrier alone, the T1-116C 21 antibody significantly reduced the growth rate of MDA-MB-231 tumors (P<0.0001). responses with a significant reduction in tumor burden, which is consistent with most 19 cancer vaccination studies, and is largely due to the immunosuppressive nature of 20 the tumor microenvironment(14,15). It is estimated that for CTL killing, the optimal 21 number of binding sites on target cells is between 80-120, while higher 22 concentrations (500-700) induce T cell hyporesponsiveness(46,47). Here, we 23 agents are similar to those for TCRs, particularly following the successful engineering 16 of high affinity recombinant TCRs to overcome their naturally low affinity. These 17 include the use of TCRm antibodies to deliver drugs or toxins, and their potential as a 18 targeting moiety for tumor targeting viruses. Importantly these approaches do not 19 require a competent immune system and thus will be suitable for immunosuppressed 20 patients lacking both immune effectors and T cells. TCRm antibodies also have the 21 potential to be used as the targeting agent on chimeric antigen receptor (CAR) 22 engineered T cells, without any potential for recombining with endogenous TCRs. 23
Future studies of multiple tumor models and normal tissue cross-reactivity profiling 24 are required to evidence sufficient efficacy and specificity, but we believe this The T1-116C antibody delays MDA-MB-231 xenograft tumor growth. MDA-MB-231 18 cells were inoculated as described above and the tumors were allowed to grow with 19 treatment starting at day 14 when the average tumor sizes reached 150mm 3 . Mice 20 were divided into groups having similar average tumor sizes and distributions (n = 9). 21 T1-116C-mIgG2a and an isotype control antibody were injected twice a week 22 (10mg/kg) i.p. until the end of the experiment. Tumor sizes were calculated as length 23
x width x height x π / 6. 24 
